NCT05166304CompletedPhase 1/2
Rebamipide in Patients With Active Rheumatoid Arthritis
Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
Although the aetiology of RA remains to be fully elucidated, interleukin (IL)-17 are believed to play a critical role in the pathogenesis of RA. Rebamipide is an antiulcer drug that protects gastric epithelial cells,improves gastric defense mechanisms by increasing gastric mucus. Rebamipide inhibited interleukin (IL)-17, also it inhibits IL-1β-induced RASF proliferation.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 8 Dec 2021
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- October 6 University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05166304
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 60
- From 1 Jan 2024 to the primary completion date, 1 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any changes in using medication (changing the dosage or type of medicines)
- Receive hormone replacement therapy, warfarin, and other anticoagulants
Other illness
- History of biological DMARDS.
- History of gastrointestinal surgery, GI ulceration,GI bleeding
- Intolerance or allergy to rebamibide or methotrexate
Other
- Smoking or alcohol abuse
Who the study is looking for
- patients with active rheumatoid arthritis (disease activity score-28 joints: DAS-28 \> 3.2) based on the 2010 American College of Rheumatology (ACR) criteria16 were recruited.
- rheumatoid Patients who received the standard therapy (i.e. one or more conventional DMARDs) for at least three months.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Minia University Coordinator of this site? Confirm its status | Minya | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.